To analyze the effects of mifepristone combined with gestrinone for treating the patients with endometriosis(EMT) on their ovarian function, inflammatory factors levels, and pregnancy rate. Methods: The data of 128 patients with endometriosis who underwent treatment from March 2019 to March 2021 were analyzed retrospectively. According to the treatment methods, these patients were divided into control group(62 cases with gestrinone treatment) and study group(66 cases with treatment of mifepristone combined with gestrinone). The levels of follicle stimulating hormone(FSH), estrogen(E2), luteinizing hormone(LH), and the progesterone(P), and the levels of ovarian function indicators, such as interleukin 4(IL-4), tumor necrosis factorα(TNF α), hypersensitive C reactive protein(hs-CRP), and interleukin 8(IL-8) of the patients in the two groups before treatment and in 6 months after treatment were observed. The characteristics of different types of EMT, the pregnancy outcomes and the adverse reactions in the 6 and 12 months of follow up after treatment of the patients in the two groups were observed. Results: The levels of ovarian function indexes and inflammatory factors of the patients in both groups after treatment had decreased significantly, and which of the patients in the study group were significantly lower than those of the patients in the control group(P＜0.05). The natural pregnancy rates of the patients in the study group in the 6 and 12 months after treatment were 47.0% and 54.5%, respectively, which were significantly higher than those(24.2% and 35.5%) of the patients in the control group. The pregnancy rates after assisted reproductive technology of the patients in the study group in the 6 and 12 months after treatment were 27.3% and 37.9%, which were significantly higher than those(12.9% and 19.4%) of the patients in the control group(all P＜0.05). There was no significant difference in the adverse reactions rate(10.6% vs.6.5%) of the patients between the two groups(P>0.05). Conclusion: Mifepristone combined with gestrinone for treating the patients with EMT can improve their levels of inflammatory factors and ovarian function indicators, and which can increase their pregnancy rate, without increasing the adverse reactions.